Exclusive Online Content
Catalent to Develop Softgel Capsules for JOT's Leading Orphan Disease Candidates
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it is…
Dalton Enters Into Agreement With USAMMDA in Support of US Army’s Drug Development Program
Dalton Pharma Services, a privately owned pharmaceutical services provider, recently announced that it has entered into a contract service agreement with the United States Army…
Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma & Consumer Healthcare Industries
Lonza Group AG, KKR, and Capsugel S.A. recently announced they have entered into a definitive agreement under which Lonza will acquire Capsugel from KKR for…
Vetter's Skokie Site Successfully Manufactures Batches on New Clinical Syringe Filling Line
Vetter, a leading international contract development and manufacturing organization (CDMO) that specializes in aseptic filling for its (bio-)pharmaceutical customers, recently announced that its new clinical…
Catalent Biologics Collaborates With PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine R&D
Catalent Pharma Solutions recently announced it has signed an agreement with PATH, an international non-profit organization and a leader in global health innovation, to advance…
Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it had…
West Announces Expanded Contract Manufacturing Capabilities in Ireland
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the completion of a 60,000 square foot…
Vetter: Choosing the Right Diluent to Help Maximize Success
Choose the Right Diluent to Help Maximize Success The biologics market continues to rise, expecting to reach $250 billion by 2024. Due to the unstable nature…
Healthcare Companies Must Embrace New Funding Sources as Venture Investment Continues to Decline
Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early stage investments,…
Ligand Partners Spectrum Pharmaceuticals & Lundbeck Receive FDA Approvals
Ligand Pharmaceuticals Incorporated recently announced that partner Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus…
Evonik Ramps Up Production Capacity for Biomaterials
Evonik is expanding its production facilities in Birmingham, AL, and Darmstadt, Germany. This will create additional capacity for the production of biodegradable polymers marketed globally…
MilliporeSigma Launches Next-Generation Technology for Advanced Live Cell Imaging
MilliporeSigma has launched the CellASIC® ONIX2 Microfluidic System for advanced live cell imaging. The system converts laboratory microscopes into powerful tools for live cell imaging…
Business Development Manager Needed at Fareva
Fareva is looking for a Business Development Manager/Director for the Northern American market, based in NJ, NYC, and CT, to manage its injectables/ophthalmics/high potent businesses.…
Cancer Vaccines Market Will Soar to $7.5 Billion by 2022
The cancer vaccines market is set to almost triple from $2.5 billion in 2015 to $7.5 billion by 2022, representing a strong compound annual growth…
Progenics Announces $50-Million Infusion to Advance Portfolio
Progenics Pharmaceuticals, Inc. recently announced its wholly owned subsidiary MNTX Royalties Sub LLC has entered into a $50-million term loan agreement with a fund managed…
Positive Results for Alkermes' Phase III Study Spell Good News for Major Depressive Disorder Space
Positive topline results have been announced by Alkermes for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), according…
Celyad's CAR-T Candidate Delivers in Early Stage Study
Celyad recently announced that first data analysis of the NKR-2 Phase I trial shows encouraging results. The NKR-2 Phase I trial is a single infusion,…
Viral Gene Announces Breakthrough in Colon Cancer
Philadelphia, PA – October 28, 2016 - Colorectal cancer kills more than 49,000 Americans each year and is the second-leading cause of cancer deaths in…
Molex Completes Acquisition of Phillips-Medisize Corporation
Molex, a global manufacturer of complete interconnect solutions, has completed its previously announced acquisition of Phillips-Medisize Corporation, a portfolio company of the San Francisco, CA-based…
Catalent Celebrates Ground Breaking for Expanded Biologics
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, celebrated its ground breaking…
